| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | Arcus Biosciences, Inc. | 4,680,716 | 6.2% | EDGAR |
| SC 13G | 2024-02-09 | FMR LLC | Arcus Biosciences, Inc. | 4,728,782 | 6.3% | EDGAR |
| SC 13D/A | 2024-01-31 | GILEAD SCIENCES, INC. | Arcus Biosciences, Inc. | 31,532,781 | 35.0% | EDGAR |
| SC 13G | 2024-01-24 | STATE STREET CORP | Arcus Biosciences, Inc. | - | 5.7% | EDGAR |
| SC 13G/A | 2024-01-23 | BlackRock Inc. | Arcus Biosciences, Inc. | 10,035,170 | 13.4% | EDGAR |
| SC 13D/A | 2023-07-06 | GILEAD SCIENCES, INC. | Arcus Biosciences, Inc. | 25,586,953 | 35.0% | EDGAR |
| SC 13G/A | 2023-02-14 | BIOTECHNOLOGY VALUE FUND L P | Arcus Biosciences, Inc. | 1,236,002 | 1.7% | EDGAR |
| SC 13G/A | 2023-02-14 | PFM Health Sciences, LP | Arcus Biosciences, Inc. | - | 3.7% | EDGAR |
| SC 13G/A | 2023-02-10 | EcoR1 Capital, LLC | Arcus Biosciences, Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2023-02-09 | VANGUARD GROUP INC | Arcus Biosciences, Inc. | 4,373,177 | 6.0% | EDGAR |
| SC 13G/A | 2023-01-26 | BlackRock Inc. | Arcus Biosciences, Inc. | 9,389,048 | 13.0% | EDGAR |
| SC 13G/A | 2023-01-20 | BlackRock Inc. | Arcus Biosciences, Inc. | 9,389,048 | 13.0% | EDGAR |
| SC 13G | 2022-10-17 | PFM Health Sciences, LP | Arcus Biosciences, Inc. | - | 5.5% | EDGAR |
| SC 13G | 2022-05-09 | BlackRock Inc. | Arcus Biosciences, Inc. | 7,967,677 | 11.1% | EDGAR |
| SC 13G | 2022-03-14 | BIOTECHNOLOGY VALUE FUND L P | Arcus Biosciences, Inc. | 2,156,510 | 3.0% | EDGAR |
| SC 13G/A | 2022-02-14 | EcoR1 Capital, LLC | Arcus Biosciences, Inc. | 5,523,358 | 7.9% | EDGAR |
| SC 13G/A | 2022-02-14 | PFM Health Sciences, LP | Arcus Biosciences, Inc. | - | 4.9% | EDGAR |
| SC 13G/A | 2022-02-14 | GV 2016, L.P. | Arcus Biosciences, Inc. | 638,967 | 0.9% | EDGAR |
| SC 13G | 2022-02-04 | BlackRock Inc. | Arcus Biosciences, Inc. | 4,129,929 | 5.9% | EDGAR |
| SC 13G | 2021-07-19 | EcoR1 Capital, LLC | Arcus Biosciences, Inc. | 4,572,047 | 6.4% | EDGAR |